Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes

Swapnil Rajpathak; Vikas Aggarwal; Frank B Hu

doi:10.1007/s11892-009-0084-8

Related publications

Article2012

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

Hicham Skali, Julie Lin, Marc A. Pfeffer, Chao-Yin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Jérôme Rossert, Patrick S. Parfrey, Nairne Scott‐Douglas, Ajay Singh, Robert D. Toto, Hajime Uno, Peter Ivanovich

Article2012

Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation.

Maurizio Paciaroni, Giancarlo Agnelli

Dataset

Faculty Opinions recommendation of Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

Giuseppe Remuzzi, Amantia Imeraj

Article2019

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease

David M. Charytan, Scott D. Solomon, Peter Ivanovich, Giuseppe Remuzzi, Mark E. Cooper, Janet B. McGill, Hans‐Henrik Parving, Patrick S. Parfrey, Ajay Singh, Emmanuel A. Burdmann, Andrew S. Levey, Kai‐Uwe Eckardt, John J.V. McMurray, Larry A. Weinrauch, Jiankang Liu, Brian Claggett, Eldrin F. Lewis, Marc A. Pfeffer

Article2013

Original Investigation Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

Hicham Skali, Julie Lin, Marc A. Pfeffer, Chaoyin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Patrick S. Parfrey, Nairne Scott‐Douglas, Ajay Singh